Drug Trial Radar · NCT00004339
Study of Tetrathiomolybdate in Patients With Wilson Disease
Last checked: Nov 20, 2026Latest source record: May 9, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jan 1994
Primary completion
Not stated
Sponsor
- Lead sponsor
- National Center for Research Resources (NCRR)NIH
- Sponsor type
- NIH
- Collaborators
- University of Michigan
- First posted
- Oct 19, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
Conditions
- Wilson Disease
Interventions
tetrathiomolybdateDrug
trientineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.